Biomedicines (Apr 2022)

Levosimendan Ameliorates Cardiopulmonary Function but Not Inflammatory Response in a Dual Model of Experimental ARDS

  • René Rissel,
  • Moritz Gosling,
  • Jens Kamuf,
  • Miriam Renz,
  • Robert Ruemmler,
  • Alexander Ziebart,
  • Erik K. Hartmann

DOI
https://doi.org/10.3390/biomedicines10051031
Journal volume & issue
Vol. 10, no. 5
p. 1031

Abstract

Read online

The calcium sensitiser levosimendan, which is used as an inodilator to treat decompensated heart failure, may also exhibit anti-inflammatory properties. We examined whether treatment with levosimendan improves cardiopulmonary function and is substantially beneficial to the inflammatory response in acute respiratory response syndrome (ARDS). Levosimendan was administered intravenously in a new experimental porcine model of ARDS. For comparison, we used milrinone, another well-known inotropic agent. Our results demonstrated that levosimendan intravenously improved hemodynamics and lung function in a porcine ARDS model. Significant beneficial alterations in the inflammatory response and lung injury were not detected.

Keywords